Reading CPT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.

QuarterlyIQ Insights · CPT

Price

Price, valuation, and the composite score on the same time axis. Scroll over the price chart to zoom.

Price

Daily closes. Earnings/event dots inline.

Close 2026-06-16

Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.

EarningsMaterial event

What it's worth (estimated)

A consensus fair price across 5 valuation methods, at three horizons. Current price $112.36. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.

12-month· primaryexpensive

$53.29consensus

Range $11.50 – $63.75

vs price: +111% above

Method agreement — · 5 methods

No-growth: today's peer multiple on trailing earnings. The headline read.

3-yearfair

$127.31consensus

Range $96.78 – $157.83

vs price: -12% below

Method agreement — · 2 methods

Embeds projected growth. Leans optimistic by design. Upside context.

5-yearfair

By method

Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.

Method	Horizon	Est. price	Multiple	Per-share input	EPS source	Confidence
Mgmt guidance	12M	$11.43	17.3	0.66	Mgmt	low
Peer P/FCF	12M	$62.90	20.4	3.08	TTM	high
Peer P/FFO	12M	$138.52	16.4	8.45	TTM	high
Own P/E history	12M	$53.69	80.5	0.67	TTM	high
triangulated

P/E history

Monthly trailing P/E with quartile reference lines.

79 monthly points available

Coming next

A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.